

Delphine Rea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/181517/publications.pdf>

Version: 2024-02-01

134
papers

10,728
citations

50170

46
h-index

31759

101
g-index

139
all docs

139
docs citations

139
times ranked

7784
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103580.	2.0	21
2	Long-term outcome of imatinib 400â€‰mg compared to imatinib 600â€‰mg or imatinib 400â€‰mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021, 35, 2332-2345.	3.3	15
3	Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study. <i>Leukemia Research</i> , 2021, 104, 106541.	0.4	4
4	Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. <i>Blood</i> , 2021, 138, 2142-2148.	0.6	23
5	Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2021, 194, 393-402.	1.2	22
6	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
7	Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2021, , 77-91.	0.2	0
8	<i>The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different</i>. <i>Blood</i> , 2021, 138, 2552-2552.	0.6	0
9	Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience. <i>Blood</i> , 2021, 138, 3604-3604.	0.6	0
10	COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. <i>Blood</i> , 2021, 138, 634-634.	0.6	5
11	Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey. <i>Blood</i> , 2021, 138, 4986-4986.	0.6	0
12	Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. <i>Leukemia and Lymphoma</i> , 2020, 61, 650-659.	0.6	93
13	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. <i>Nature Communications</i> , 2020, 11, 5938.	5.8	22
14	Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?. <i>Blood Advances</i> , 2020, 4, 5589-5594.	2.5	4
15	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	1.2	14
16	Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 243-247.	0.9	0
17	Expert opinionâ€™ management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , 2020, 34, 1495-1502.	3.3	63
18	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. <i>Annals of Hematology</i> , 2020, 99, 897-898.	0.8	1

#	ARTICLE	IF	CITATIONS
19	COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. <i>Blood</i> , 2020, 136, 46-47.	0.6	17
20	NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2020, 136, 36-36.	0.6	2
21	<i>CSF3B1</i> mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2020, 136, 1-1.	0.6	4
22	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. <i>Blood</i> , 2020, 136, LBA-5-LBA-5.	0.6	1
23	Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF). <i>Blood</i> , 2020, 136, 8-8.	0.6	2
24	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 346-357.	2.0	96
25	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. <i>Haematologica</i> , 2019, 104, 93-101.	1.7	62
26	Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission. <i>Cancer Medicine</i> , 2019, 8, 4976-4985.	1.3	13
27	Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6606-6613.	3.2	82
28	Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. <i>British Journal of Haematology</i> , 2019, 187, 337-346.	1.2	31
29	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. <i>Cancer Cell</i> , 2019, 36, 431-443.e5.	7.7	137
30	Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 492-500.	1.2	10
31	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326.	13.9	257
32	Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. <i>Cancer</i> , 2018, 124, 2956-2963.	2.0	63
33	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , 2018, 19, 747-757.	5.1	444
34	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	0.6	392
35	Treatment-free remission in patients with chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2018, 108, 355-364.	0.7	35
36	How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. <i>British Journal of Haematology</i> , 2018, 180, 24-32.	1.2	27

#	ARTICLE	IF	CITATIONS
37	Management of ITK pulmonary and pleural adverse effects: Fi-LMC guidelines. <i>Hematologie</i> , 2018, 24, 134-144.	0.0	0
38	Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. <i>Experimental Hematology</i> , 2018, 67, 41-48.	0.2	34
39	Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. <i>American Journal of Hematology</i> , 2018, 93, E342-E345.	2.0	13
40	Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up. <i>Blood</i> , 2018, 132, 4255-4255.	0.6	6
41	What is treatment free remission in chronic myeloid leukemia?. <i>Oncotarget</i> , 2018, 9, 4279-4279.	0.8	1
42	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1225-1233.	1.2	9
43	Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. <i>Haematologica</i> , 2017, 102, 1368-1377.	1.7	114
44	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1585-1596.	1.2	29
45	Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. <i>Blood</i> , 2017, 129, 846-854.	0.6	268
46	Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 52-59.	2.0	38
47	Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. <i>Cancer</i> , 2017, 123, 4403-4410.	2.0	85
48	Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). <i>Leukemia Research</i> , 2017, 60, 94-102.	0.4	19
49	Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 298-305.	0.8	380
50	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , 2016, 48, 1517-1519.	3.1	44
51	Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1302-1305.	0.3	1
52	Dasatinib in imatinib-resistant or intolerant chronic phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180034. <i>American Journal of Hematology</i> , 2016, 91, 869-874.	2.0	145
53	Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2016, , 71-87.	0.2	0
54	Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 169-174.	0.2	25

#	ARTICLE	IF	CITATIONS
55	Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study. <i>Blood</i> , 2016, 128, 1895-1895.	0.6	23
56	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase. <i>Blood</i> , 2016, 128, 3094-3094.	0.6	11
57	Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. <i>Blood</i> , 2016, 128, 625-625.	0.6	20
58	Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. <i>Oncotarget</i> , 2016, 7, 35293-35301.	0.8	54
59	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115
60	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. <i>Blood</i> , 2015, 125, 901-906.	0.6	239
61	Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. <i>American Journal of Hematology</i> , 2015, 90, 1060-1064.	2.0	98
62	Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e37-e46.	2.2	45
63	Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic or accelerated phase chronic myeloid leukemia: Results with 24 months of follow-up. <i>Cancer</i> , 2015, 121, 1637-1644.	2.0	44
64	Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy. <i>European Journal of Haematology</i> , 2015, 95, 480-483.	1.1	2
65	Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 149-158.	0.8	48
66	Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 1206-1209.	3.3	38
67	Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. <i>European Journal of Haematology</i> , 2015, 94, 363-367.	1.1	25
68	Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC). <i>Blood</i> , 2015, 126, 134-134.	0.6	10
69	Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort. <i>Blood</i> , 2015, 126, 137-137.	0.6	14
70	ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single-Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. <i>Blood</i> , 2015, 126, 138-138.	0.6	22
71	Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results. <i>Blood</i> , 2015, 126, 1578-1578.	0.6	2
72	Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. <i>Blood</i> , 2015, 126, 4025-4025.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. <i>Blood</i> , 2015, 126, 4040-4040.	0.6	7
74	Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. <i>Blood</i> , 2015, 126, 479-479.	0.6	1
75	ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3652-3652.	0.6	1
76	Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. <i>Blood</i> , 2015, 126, 5142-5142.	0.6	0
77	Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. <i>Blood</i> , 2015, 126, 4054-4054.	0.6	0
78	Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study. <i>Blood</i> , 2015, 126, 4039-4039.	0.6	0
79	Reply to J. Richter et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 2823-2825.	0.8	11
80	Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. <i>Haematologica</i> , 2014, 99, 1197-1203.	1.7	114
81	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
82	Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease. <i>Journal of Clinical Oncology</i> , 2014, 32, 424-430.	0.8	355
83	Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale. <i>Clinical Biochemistry</i> , 2014, 47, 1333-1336.	0.8	10
84	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. <i>Blood</i> , 2014, 124, 729-736.	0.6	84
85	Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2212-2212.	0.6	0
86	A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. <i>Transfusion</i> , 2013, 53, 564-569.	0.8	30
87	Tolerability and efficacy of pegylated interferon- α 2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2013, 119, 4284-4289.	2.0	16
88	Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 150-155.	2.0	140
89	Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study. <i>American Journal of Hematology</i> , 2013, 88, 1-4.	2.0	25
90	Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2013, 122, 3082-3084.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, e78-e79.	1.7	22
92	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. <i>Blood</i> , 2013, 122, 650-650.	0.6	8
93	Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib. <i>Blood</i> , 2013, 122, 654-654.	0.6	41
94	First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. <i>Leukemia</i> , 2012, 26, 2254-2259.	3.3	37
95	Imatinib Sensitizes T-cell Lymphocytes From Chronic Myeloid Leukemia Patients to FasL-induced Cell Death. <i>Journal of Immunotherapy</i> , 2012, 35, 154-158.	1.2	8
96	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. <i>Blood</i> , 2012, 120, 2573-2580.	0.6	123
97	Curing Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 103-108.	1.2	24
98	Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 817-825.	0.4	51
99	Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the <i>BCR-ABL1</i> T315I gatekeeper mutation. <i>British Journal of Haematology</i> , 2012, 157, 407-410.	1.2	14
100	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-”The GFM experience. <i>Leukemia Research</i> , 2011, 35, 1444-1448.	0.4	36
101	Severe Peripheral Arterial Disease During Nilotinib Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1347-1348.	3.0	145
102	The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFRO1 study). <i>Leukemia Research</i> , 2011, 35, 777-782.	0.4	27
103	Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?. <i>Haematologica</i> , 2011, 96, 664-671.	1.7	25
104	Recommandations duÂgroupe FI-LMC pourÂlaÂprise enÂcharge desÂpatients prÃ©sentant desÂmutations duÂdomaine tyrosine kinase deÂBCR-ABL dansÂlesÂhÃ©mopathies malignes Âchromosome Philadelphia. <i>Hematologie</i> , 2010, 16, 65-79.	0.0	7
105	Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 363, 2511-2521.	13.9	362
106	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. <i>Lancet Oncology</i> , The, 2010, 11, 1029-1035.	5.1	1,359
107	Aspects pratiques desÂtraitements parÂinhibiteurs deÂtyrosine kinase dansÂlaÂleucÃ©mie myÃ©loÃ©de chronique. <i>Hematologie</i> , 2009, 15, 197-202.	0.0	1
108	Combined Chemotherapy (daunorubicin + cytarabine) and Dasatinib as Salvage Therapy of Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis, a Pilot Study.. <i>Blood</i> , 2009, 114, 2195-2195.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Dasatinib-induced lupus. <i>Lancet</i> , The, 2008, 372, 713-714.	6.3	20
110	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 3204-3212.	0.8	458
111	Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 814-818.	2.5	189
112	Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. <i>Blood</i> , 2007, 109, 58-60.	0.6	505
113	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. <i>Blood</i> , 2007, 109, 1408-1413.	0.6	300
114	Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells. <i>Cellular Microbiology</i> , 2007, 9, 1412-1425.	1.1	40
115	Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2007, 137, 248-251.	1.2	41
116	Quantification of nucleated red blood cells in allogeneic marrow graft and impact of processing on recovery. <i>Transfusion</i> , 2007, 47, 266-271.	0.8	1
117	ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery. <i>Transfusion</i> , 2006, 46, 398-402.	0.8	34
118	Prospective flow cytometric evaluation of nucleated red blood cells in cord blood units and relationship with nucleated and CD34+ cell quantification. <i>Transfusion</i> , 2006, 46, 403-406.	0.8	16
119	High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. <i>Leukemia</i> , 2006, 20, 400-403.	3.3	67
120	BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia. <i>Journal of Immunology</i> , 2006, 176, 5108-5116.	0.4	126
121	Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. <i>Journal of Leukocyte Biology</i> , 2006, 79, 747-756.	1.5	19
122	Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. <i>Leukemia</i> , 2004, 18, 1656-1661.	3.3	79
123	Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. <i>European Journal of Immunology</i> , 2004, 34, 565-575.	1.6	99
124	Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells. <i>Human Immunology</i> , 2004, 65, 1344-1355.	1.2	15
125	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2326-2334.	0.8	146
126	Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. <i>Transplantation</i> , 2003, 76, 1608-1615.	0.5	71

#	ARTICLE	IF	CITATIONS
127	Strategies for improved antigen delivery into dendritic cells. Trends in Molecular Medicine, 2001, 7, 91-94.	3.5	17
128	Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte-Induced Apoptosis. Journal of Experimental Medicine, 2001, 194, 657-668.	4.2	187
129	The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells. Cancer Immunology, Immunotherapy, 2001, 49, 671-678.	2.0	11
130	Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells. Journal of Immunology, 2001, 166, 5236-5244.	0.4	149
131	Immature Dendritic Cells Acquire Cd8+ Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cell-Independent or -Dependent Stimuli. Journal of Experimental Medicine, 2000, 192, 145-150.	4.2	173
132	Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood, 2000, 95, 3162-3167.	0.6	154
133	Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset. Journal of Virology, 1999, 73, 10245-10253.	1.5	145
134	In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. European Journal of Immunology, 1992, 22, 2937-2942.	1.6	116